By Andrew Tan, Urologist, Prostate & Kidney Surgeon, Nedlands
Over the past decade, the management of clinically significant, localised prostate cancer has undergone a significant evolution.
While radical prostatectomy and external beam radiotherapy remain the gold standards for many patients, the associated morbidity – particularly impacting sexual function and urinary continence – has prompted interest in less invasive strategies.
Focal therapy has emerged as a promising middle ground, offering the potential for effective cancer control with minimal impact on quality of life....
Over the past decade, the management of clinically significant, localised prostate cancer has undergone a significant evolution.
While radical prostatectomy and external beam radiotherapy remain the gold standards for many patients, the associated morbidity – particularly impacting sexual function and urinary continence – has prompted interest in less invasive strategies.
Focal therapy has emerged as a promising middle ground, offering the potential for effective cancer control with minimal impact on quality of life....
This content is restricted to site members. If you are an existing user, please log in. New users may register below.